3B11-N, A Monoclonal Antibody Against Mers-Cov, Reduces Lung Pathology In Rhesus Monkeys Following Intratracheal Inoculation Of Mers-Cov Jordan-N3/2012

Keywords

Animal model, MERS; Antibody therapy; Human monoclonal antibody therapy; MERS-CoV; Respiratory syndrome

Abstract

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×106 PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.

Publication Date

3-1-2016

Publication Title

Virology

Volume

490

Number of Pages

49-58

Document Type

Article

Personal Identifier

scopus

DOI Link

https://doi.org/10.1016/j.virol.2016.01.004

Socpus ID

84961381392 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/84961381392

This document is currently not available here.

Share

COinS